Translational Development Acquisition (TDACW) Non-Current Deffered Revenue (2024 - 2026)

Translational Development Acquisition (TDACW) has reported Non-Current Deffered Revenue for 3 consecutive years, with $6.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non-Current Deffered Revenue changed 0.0% year-over-year to $6.0 million; the trailing twelve-month figure through Jun 2026 stood at $6.0 million (changed 0.0% YoY), and the FY2025 full-year result was $6.0 million, changed 0.0% from the prior year.
• Non-Current Deffered Revenue held at $6.0 million in Q2 2026 per TDACW's latest filing, from $6.0 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $6.0 million in Q4 2024 and bottomed at $6.0 million in Q4 2024.
• Historically, Non-Current Deffered Revenue has averaged $6.0 million across 3 years, with a median of $6.0 million in 2024.
• The widest YoY moves for Non-Current Deffered Revenue: up 0.0% in 2025, down 0.0% in 2025.
• Over 3 years, Non-Current Deffered Revenue stood at $6.0 million in 2024, then changed by 0.0% to $6.0 million in 2025, then changed by 0.0% to $6.0 million in 2026.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $6.0 million, $6.0 million, and $6.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.